Posters/Publications

Title
Venue
Type
Date

Significant lipid lowering by ASC41, an oral tablet, liver-targeted THRβ agonist, in a phase I randomized, double-blind, placebo controlled single- and multiple-ascending dose study

EASL International Liver Congress

poster

04/2021
Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC42, a novel non-steroidal FXR agonist, in High Fat Diet Induced NASH mice

EASL International Liver Congress

poster

04/2021
Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR-β Agonist, in High Fat Diet Induced NASH SD Rats

EASL International Liver Congress

poster

04/2021